Host |
Rabbit |
Klon |
ZR217 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human FLI1 protein |
Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
0.5 ml |
Concentrate |
RUO |
Z2498RS-R |
-
|
Host |
Rabbit |
Klon |
ZR217 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human FLI1 protein |
Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
0.1 ml |
Concentrate |
RUO |
Z2498RT-R |
-
|
Host |
Rabbit |
Klon |
SP123 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the N-terminus of mouse FLK-1 protein |
Lokalisation |
Cell Membrane |
FLK-1 (mouse)
|
Zytomed Systems GmbH |
SP123 |
0.5 ml |
Concentrate |
RUO |
506-4232 |
-
|
Host |
Rabbit |
Klon |
SP123 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near the N-terminus of mouse FLK-1 protein |
Lokalisation |
Cell Membrane |
FLK-1 (mouse)
|
Zytomed Systems GmbH |
SP123 |
1 ml |
Concentrate |
RUO |
506-4234 |
-
|
Host |
Mouse |
Klon |
BGN/1210/55 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Folate binding protein from bovine milk |
Folate Binding Protein
|
Zytomed Systems GmbH |
BGN/1210/55 |
200 µg |
Purified |
RUO |
606-0136 |
-
|
Host |
Rabbit |
Klon |
SP88 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Prostate |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide derived from near C-terminus of human FOXA1 protein |
Lokalisation |
Nuclear in prostate |
FOXA1
|
Zytomed Systems GmbH |
SP88 |
1 ml |
Concentrate |
RUO |
506-3884 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
506-19060 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
506-19062 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
506-19064 |
-
|
Host |
Rabbit |
Klon |
ZR333 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant Human FOXP1 protein |
Lokalisation |
Nuclear |
FOXP1
|
Zeta Corporation |
ZR333 |
0.1 ml |
Concentrate |
CE/IVD |
Z2639RT |
-
|
Host |
Rabbit |
Klon |
SP97 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human FoxP3 protein |
Lokalisation |
Nucleus |
FOXP3
|
Zytomed Systems GmbH |
SP97 |
0.1 ml |
Concentrate |
RUO |
506-3970 |
-
|
Host |
Rabbit |
Klon |
SP97 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human FoxP3 protein |
Lokalisation |
Nucleus |
FOXP3
|
Zytomed Systems GmbH |
SP97 |
0.5 ml |
Concentrate |
RUO |
506-3972 |
-
|
Host |
Rabbit |
Klon |
SP97 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human FoxP3 protein |
Lokalisation |
Nucleus |
FOXP3
|
Zytomed Systems GmbH |
SP97 |
1 ml |
Concentrate |
RUO |
506-3974 |
-
|
Host |
Mouse |
Klon |
86D |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer, tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
86D |
0.1 ml |
Concentrate |
CE/IVD |
ACI3197A |
-
|
Host |
Mouse |
Klon |
86D |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer, tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
86D |
1 ml |
Concentrate |
CE/IVD |
ACI3197C |
-
|
Host |
Mouse |
Klon |
236A/E7 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer, melanoma |
Verdünnung |
- |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
236A/E7 |
6 ml |
Ready-to-use |
CE/IVD |
API3164AA |
-
|
Host |
Mouse |
Klon |
86D |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer, tonsil |
Verdünnung |
- |
Isotyp |
IgG1 |
Lokalisation |
Nucleus |
FOXP3
|
Biocare Medical |
86D |
6 ml |
Ready-to-use |
CE/IVD |
API3197AA |
-
|
Host |
Rabbit |
Klon |
ZR246 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length hFSH beta sub-unit |
Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
1 ml |
Concentrate |
CE/IVD |
Z2721RL |
-
|
Host |
Rabbit |
Klon |
ZR246 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length hFSH beta sub-unit |
Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
7 ml |
Concentrate |
CE/IVD |
Z2721RP |
-
|
Host |
Rabbit |
Klon |
ZR246 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length hFSH beta sub-unit |
Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
0.5 ml |
Concentrate |
CE/IVD |
Z2721RS |
-
|
Host |
Rabbit |
Klon |
ZR246 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length hFSH beta sub-unit |
Lokalisation |
Cytoplasm |
FSH
|
Zeta Corporation |
ZR246 |
0.1 ml |
Concentrate |
CE/IVD |
Z2721RT |
-
|
Host |
Mouse |
Klon |
BGN/F63/02 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Intact Follicle Stimulating Hormone |
FSH (Follicle Stimulating Hormone)
|
Zytomed Systems GmbH |
BGN/F63/02 |
1 mg |
Purified |
RUO |
606-0161 |
-
|
Host |
Mouse |
Klon |
GAL3-3B8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Papillary thyroid carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Galectin-3
|
Biocare Medical |
GAL3-3B8 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3174A |
-
|
Host |
Mouse |
Klon |
GAL3-3B8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Papillary thyroid carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Galectin-3
|
Biocare Medical |
GAL3-3B8 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3174B |
-
|
Host |
Mouse |
Klon |
GAL3-3B8 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Papillary thyroid carcinoma |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Galectin-3
|
Biocare Medical |
GAL3-3B8 |
6 ml |
Ready-to-use |
CE/IVD |
API3174AA |
-
|
Host |
Mouse |
Klon |
H-5 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
1 ml |
Concentrate |
CE/IVD |
MOB541 |
-
|
Host |
Mouse |
Klon |
H-5 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
colon carcinoma, papillary thyroid carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB541-01 |
-
|
Host |
Mouse |
Klon |
H-5 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB541-05 |
-
|
Host |
Mouse |
Klon |
H-5 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoms |
Verdünnung |
- |
Isotyp |
IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM541 |
-
|
Host |
Mouse |
Klon |
H-5 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma, papillary thyroid carcinoma |
Verdünnung |
- |
Isotyp |
IgG1 |
Galectin-3
|
Diagnostic Biosystems |
H-5 |
25 ml |
Ready-to-use |
CE/IVD |
PDM541-25 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM182 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Papillary or follicular thyroid carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
1 ml |
Concentrate |
CE/IVD |
Z2487ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM182 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Papillary or follicular thyroid carcinoma |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
7 ml |
Ready-to-use |
CE/IVD |
Z2487MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM182 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Papillary or follicular thyroid carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
0.5 ml |
Concentrate |
CE/IVD |
Z2487MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM182 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Papillary or follicular thyroid carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human LGALS3 protein (aa 150-200) |
Lokalisation |
Cytoplasm |
Galectin-3
|
Zeta Corporation |
ZM182 |
0.1 ml |
Concentrate |
CE/IVD |
Z2487MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Stomach |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR027 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Stomach |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP044 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Stomach |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP044-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Stomach |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Gastrin
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP044-05 |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Urothelial carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
1.0 ml |
Concentrate |
CE/IVD |
Z2227ML |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Urothelial carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
7 ml |
Ready-to-use |
CE/IVD |
Z2227MP |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Urothelial carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
0.5 ml |
Concentrate |
CE/IVD |
Z2227MS |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Urothelial carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Conserved peptide between the GATA trans-activation and DNA-binding domain |
Lokalisation |
Nucleus |
GATA-3
|
Zeta Corporation |
L50-823 |
0.1 ml |
Concentrate |
CE/IVD |
Z2227MT |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
7 ml |
Ready-to-use |
CE/IVD |
ALI405G7 |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
0.1 ml |
Concentrate |
CE/IVD |
CM405A |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
0.5 ml |
Concentrate |
CE/IVD |
CM405B |
-
|
Host |
Mouse |
Klon |
L50-823 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nucleus |
GATA3
|
Biocare Medical |
L50-823 |
6 ml |
Ready-to-use |
CE/IVD |
PM405AA |
-
|
Host |
Mouse + Mouse |
Klon |
L50-823 + BC21 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Bladder cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa + Mouse IgG1 kappa |
Lokalisation |
Nuclear + Cytoplasmic/membrane |
GATA3 + Uroplakin II
|
Biocare Medical |
L50-823 + BC21 |
6 ml |
Ready-to-use |
CE/IVD |
API3173AA |
-
|
Host |
Mouse |
Klon |
DBM15.52 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a kappa |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15
|
Diagnostic Biosystems |
DBM15.52 |
1 ml |
Concentrate |
CE/IVD |
MOB526 |
-
|
Host |
Mouse |
Klon |
DBM15.52 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a kappa |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15
|
Diagnostic Biosystems |
DBM15.52 |
0.1 ml |
Concentrate |
CE/IVD |
MOB526-01 |
-
|
Host |
Mouse |
Klon |
DBM15.52 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a kappa |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15
|
Diagnostic Biosystems |
DBM15.52 |
0.5 ml |
Concentrate |
CE/IVD |
MOB526-05 |
-
|